← Back to patent-cliff list
Dordaviprone
Tier C — Watch / tradeDordaviprone
Oncoceutics Inc
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ClpP, DRD2
Brand：Modeyso
Indications (approved)：Diffuse midline glioma
Regional status
US
Approved
2025-08-06
EU
Phase III
2022-09-29
China
Phase I
2023-07-28
Japan
Approved
2026-09-16
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Dordaviprone?
Approved indications include: Diffuse midline glioma.
When does the Dordaviprone patent expire?
No public expiry year is available for Dordaviprone yet; this page updates once verified.
How do I get a quote for Dordaviprone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01